Top Story

Delayed HCV therapy may increase liver-related deaths

February 27, 2015

SEATTLE — Deferring treatment for hepatitis C virus infection 1 year or more after diagnosis or until evidence of advanced liver disease may increase liver-related mortality, according to data presented at CROI 2015.

“There has been debate on whether it is safe to defer HCV therapy until advanced liver disease, especially in people who live with HIV who often have other risk factors for liver disease progression,” Cindy Zahnd, researcher at the Institute of Social and Preventive Medicine, University of Bern in Switzerland, said during her presentation. “This is exactly what we wanted to assess, by modeling the impact of deferring HCV therapy until advanced liver disease, stages F3 or F4, vs. treating them sooner.”

Severe fibrosis, cirrhosis prevalent in birth cohort of HCV patients Meeting News Coverage

Severe fibrosis, cirrhosis prevalent in birth cohort of HCV patients

February 27, 2015
SEATTLE — Many adults with hepatitis C virus born between 1945 and 1965 had severe fibrosis or cirrhosis, according to data presented at CROI 2015.“Our…

ACIP confirms recommendation for annual influenza vaccination

February 27, 2015
In a unanimous decision, the CDC’s Advisory Committee on Immunization Practices supported the recommendation that all people aged 6 months and older be vaccinated…
thumbnail for video 4083320513001 Meeting News CoverageVideo

Video: Highlights in cancer and HIV treatments at CROI 2015

February 27, 2015
Infectious Disease News Editorial Board member Paul Volberding, MD, reviews HIV and cancer treatment data presented here at CROI 2015. Highlights include cervical…
Meeting News Coverage

Statins reduced non-calcified coronary plaque in HIV patients

February 27, 2015
SEATTLE — Statin therapy may reduce the volume of non-calcified coronary plaque in patients with HIV and subclinical atherosclerosis, according to data presented…
More News Headlines »
CME CNE CPE Video
Advances in Pharmacokinetic Enhancers in HIV Treatment: What You Need to Know to Optimize Outcomes

Advances in Pharmacokinetic Enhancers in HIV Treatment: What You Need to Know to Optimize Outcomes

This activity is supported by an educational grant from Bristol-Myers Squibb.

Protease inhibitors (PIs) have played an instrumental role in decreasing mortality andmorbidity among HIV-infected…
More »
Meeting News Coverage Video
thumbnail for video 4083036415001

Video: PrEP promising, but requires more exploration

February 26, 2015
SEATTLE — Raphael J. Landovitz, MD, of the
More »
CME
HBV

Critical Issues in HBV
HBV Management in Complex Populations: Volume 1, Number 2

This activity is supported by an educational grant from Gilead Sciences Medical Affairs.

Hepatitis B virus (HBV) infection is a global epidemic with a worldwide burden. Physicians must address the importance…
More »